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Tau is amicrotubule-associated protein that plays an important role in axonal stabilization,
neuronal development, and neuronal polarity. In this review, we focus on the primary,
secondary, tertiary, and quaternary tau structures. We describe the structure of tau from
its specific residues until its conformation in dimers, oligomers, and larger polymers in
physiological and pathological situations.
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Tau is a neuronal protein that was found (Weingarten et al., 1975) associated to microtubules,
together with other microtubule-associated proteins (see Matus, 1988 for a review). Tau protein
plays a role in microtubule assembly and dynamics that may regulate neuron morphology (Drubin
and Kirschner, 1986; Caceres and Kosik, 1990; Panda et al., 1999). The roles of tau in axon
development and navigation (Dawson et al., 2001; Sayas et al., 2015), dendritic spine function
(Ittner et al., 2010), or long-term depression (Takashima, 2012), have been described.
Tau protein(s) is (are) encoded by a single gene, mapt, that is located on chromosome 17 in
humans (Neve et al., 1986). This gene is transcribed into a nuclear RNA that yields six different
isoforms, lacking or containing exons 2, 3, and 10 by alternative splicing (Avila et al., 2004;
Andreadis, 2006). Exon 10 contains a microtubule-binding region similar, but not identical, to
other three additional microtubule-binding regions. Thus, isoforms containing exon 10, resulting
in tau with four microtubule (tubulin)-binding regions (repeats) are known as tau 4R, whereas
alternative spliced isoforms, lacking exon 10, are known as tau 3R.
TAU PRIMARY STRUCTURE
As previously indicated, there are mainly six tau isoforms in brain [and central nervous system
(CNS)], showing differences in their primary structure due to the presence or absence of some
specific exons. In addition, in peripheral nervous system there are additional tau isoforms
containing an extra exon, exon 4a (Goedert et al., 1992). However, the longest human CNS tau
isoform with 441 residues has usually been chosen as a model to exemplify tau primary structure
(Goedert et al., 1989). That isoform contains exons 1, 2, 3, 4, 5, 7, 9, 10, 11, 12, and 13. Within those
441 residues there is a high proportion (80) of phosphorylable residues (serine and threonine) and a
low proportion, compared to other proteins, of hydrophobic aminoacids [alanine (34), valine (25),
isoleucine (15), leucine (20), methionine (5), phenylalanine (3), tyrosine (5) or tryptophan (0)].
Phylogenetic analyses of proteins with tau-like microtubule-binding regions have indicated
the existence of a protein family of microtubule-associated proteins composed by tau, MAP2,
and MAP4 proteins. Also, similarities with some proteins from invertebrate organisms and with
a histone acetyltransferase subunit (KANSL1), have been recently reported (Sündermann et al.,
2016).
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Comparison of sequences of tau proteins from different
origins has indicated a larger variability at the N-terminal half
of tau than at C-terminal tau (Leon-Espinosa et al., 2013).
Interestingly, the localization of threonine (or alanine) residues
do not present a random distribution and they are present in
a higher proportion at the N-terminal region of tau protein
(Avila et al., 2012). Regarding the possible function of exons
2 and 3, it has been described that they might play a role
in the association of tau protein with different cell membrane
proteins like apolipoprotein ApoA1 (preferentially binding to tau
with those exons) or synaptophysin (preferentially binding tau
without those exons; Liu C. et al., 2016). Curiously, a binding
site for NRF2, a transcription factor involved in antioxidant
responses, is present in the first intron of the mapt gene and it
may facilitate exon 3 inclusion in tau protein, an inclusion that
could have a protective role (Wang et al., 2016).
Another important feature related to the primary structure of
tau protein is the presence of different types of posttranslational
modifications (PTMs) of specific residues. Among these
modifications are phosphorylation, acetylation, deamidation,
methylation, O-Glycylation, or ubiquitination (Avila et al., 2004;
Avila, 2009; Morris et al., 2015; Huang et al., 2016; Iqbal et al.,
2016). Furthermore, loss of N-terminal or C-terminal regions by
truncation are very well-known (García-Sierra et al., 2008; Avila
et al., 2015).
FIGURE 1 | Tau residues and tau regions. (A) The localization in tau molecules of some tau residues is shown. (B) The different tau regions, including the
microtubule binding repeats are shown. (C) Intramolecular interactions, like that described for “paper-clip” structure (see text and reference, Jeganathan et al., 2006)
could prevent the tau self-interaction by masking the region(s) involved in that interaction.
Although tau protein has been considered as an intrinsically
disordered protein (IDP), modifications by phosphorylation or
other posttranslational modifications could facilitate a “gain” in
secondary structure that could facilitate the appearance of α-helix
or β-sheet regions (see below).
Focus in Specific Tau Residues
As previously mentioned, primary structure of tau protein can
be divided into two regions, N-terminal, and C-terminal regions.
The C-terminal part shows less variability among tau proteins
from different species. This fact may suggest that some of these
conserved residues could be essential for some tau functions.
Hence, related to tau functions, we have selected 11 of the
conserved residues that could be important for human tau’s role.
Only three of them are at the N-terminal half of the protein. The
chosen residues are: M11, A152, K174, S214, T231, R279, K280,
C322, N368, S409, and D421 (Figure 1A shows some of them).
Methionine 11 could be the first residue for a tau truncated
protein, in the absence of the first methionine. Tau protein
starting at M11, has a decreased interaction with Alz50 antibody
suggesting possible changes in the putative tau tertiary structure
(Carmel et al., 1996; see below).
Lysine 174 can be acetylated. This modification results in a
toxic protein (Min et al., 2015). Serine 214 can be phosphorylated
by protein kinase A (Scott et al., 1993) and it has been suggested
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that this modification might play a positive role in the binding
of tau to microtubules (García de Ancos et al., 1993). Threonine
231 is followed by two proline residues. T231 is modified by
different proline directed kinases like GSK3, JNK, MAPK or cdk5
(Illenberger et al., 1998; Reynolds et al., 2000). As indicated,
T231 can be phosphorylated and the following prolines can
have a cis or trans conformation which could regulate the
posterior dephosphorylation of P-T231 (Lu et al., 1999). This
is an important task since the presence of this phosphoprotein
could be toxic (Nakamura et al., 2012). Also, P-T231 is present
in peripheral nervous system in submandibular gland and,
curiously, the level of phosphorylation decreases with increasing
Braak stage of Alzheimer disease (Dugger et al., 2016). Tau is
mainly an axonal protein. However, in Alzheimer disease and
other tauopathies it is also present at dendritic spines where may
play a toxic role. This toxic role could be the consequence of tau
modifications like phosphorylation, truncation, or acetylation.
The knowledge of the role of acetylated tau in tauopathies
is increasing gradually. For example, in the work of Tracy
et al. is described, in an elegant way, a possible mechanism
explaining the role of acetylated tau (at lysines 274 and 281).
In this article, memory impairment is studied by using a mouse
model which express human tau with lysine to glutamine
mutations to mimic lysine acetylation (Tracy et al., 2016).
Acetylated tau reduces the levels of kidney and brain expressed
protein (KIBRA) present at synapses and this may produce
a decrease in synaptic efficiency (Tracy et al., 2016). More
recently, it has been shown that acetylated tau (at lysines 274
and 281) destabilizes the cytoskeleton in the axon initial segment
(Sohn et al., 2016).
Arginine 279 can be deaminated (Dan et al., 2013) and
deamination results in a reduced ability of modified tau to bind
to microtubules (Dan et al., 2013) and perhaps it could facilitate
its self-aggregation (Montejo de Garcini et al., 1986).
Lysine 280 loss facilitates tau self-assembly and exacerbates
tau toxicity (Gorsky et al., 2016; Wang and Mandelkow, 2016).
Cysteine 322 is modified by oxidation, a modification
that regulates tau self-assembly (Kim et al., 2015; Wang and
Mandelkow, 2016).
Cleavage of asparagine 368 by an asparaginase results in the
appearance of a very toxic fragment (Zhang et al., 2014).
Serine 409 is a good substrate for Rho kinase and other
related kinases (Amano et al., 2003). Recently, it has been
suggested that ROCK phosphorylates tau protein decreasing its
further degradation (mainly for Tau4R). This may result in tau
accumulation, as occurs in some tauopathies like corticobasal
degeneration or progressive supranuclear palsy. As a results, the
use of ROCK inhibitors has been suggested for the treatment of
those diseases (Gentry et al., 2016).
Finally, truncation of aspartic 421 facilitates tau aggregation
and toxicity (García-Sierra et al., 2008) and phosphorylation at
serine 422 could enhance SDS-stable dimer formation (Tiernan
et al., 2016).
Other residues could be relevant because they can be modified
by phosphorylation (see review by Hanger et al., 2009) or
because their mutations could facilitate the development of some
tauopathies (for a review see Goedert and Jakes, 2005).
A recent example of aminoacid changes resulting in toxic
function is the mutation of alanine 152 to threonine which
causes age-dependent neuronal dysfunction, possibly through a
mechanism in whichNMDA receptors could be involved (Decker
et al., 2016; Maeda et al., 2016). The consequences of having
A152T mutation are different than those due to the presence of
other tau mutations. Commonly, tau mutations could facilitate
the assembly of large tau polymers. However, A152T mutation
promotes the formation of smaller toxic tau oligomers. In this
way, using a C. elegans tauopathy model, expressing A152T tau
mutant, it was found a reduced lifespan and severe locomotor
deficits. This pathology was due to the presence of the indicated
toxic tau oligomers but not to that of insoluble aggregates (Pir
et al., 2016).
Tau Regions or Motifs Involved in the
Binding of Tau to Other Proteins
Tau, α-Tubulin Binding Protein
The development of the mammalian CNS requires the
generation, migration, and differentiation of neurons. Each
of these cellular events needs a highly dynamic microtubule
cytoskeleton. It is necessary for, among others, the separation of
chromatids in mitosis, nuclear translocation during migration,
and the outgrowth of neurites. Microtubules are polymers
composed of globular subunits of α- and β-tubulin, two
members of one of the largest families of genes and proteins
(Turk et al., 2015). These two families of tubulins, with an
approximate molecular mass of 50 kDa, are GTP-binding
proteins and form an αβ-tubulin heterodimer which represents
the structural and functional unit of the microtubule. It has been
thought for a long time that the GTP-bound to the α subunit
(non-exchangeable) is never hydrolyzed being inaccessible for
biochemical manipulations, while those bound to the β subunit
(exchangeable) are hydrolyzed twice. First, during the formation
of the dimer and second, after microtubule incorporation.
The process of tubulin folding follows a sophisticated pathway
in which several molecular chaperones are involved. α and β
subunits are folded independently with the GTP bound to each
one. Among all the chaperones involved, including CCT and
prefoldin, tubulin folding cofactors are molecular chaperones
specifically required for αβ-tubulin dimer formation and the
acquisition of its quaternary structure (Serna and Zabala, 2016).
On the other hand, as adult neurons are not dividing cells,
they need to stabilize the microtubule cytoskeleton in order to
maintain neuronal processes such as the fast axonal transport
through long distances. Tau was identified (1–3) as a microtubule
associated protein mainly expressed in neurons. The main role of
tau is the stabilization of the axonal microtubules contributing
to decrease their intrinsic dynamic instability. Furthermore,
tau maturation implies a fine regulation of its expression in
order to produce appropriate amounts of different isoforms
by alternative splicing. This is because the isoforms regulate
differentially microtubule dynamics (Amos, 2004). Paclitaxel
is considered a mitotic inhibitor for its ability to stabilize
microtubules suppressing their dynamic, which is a requirement
for a proper cell division. For this reason, it is widely used
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in cancer treatment. Extensive studies have been directed to
the precise understanding of the interaction site in the β-
tubulin subunit. Paclitaxel and different microtubule-stabilizing
compounds such as epothilones compete at the same general
site for binding to microtubules, although paclitaxel does not
bind to yeast microtubules, for they share overlapping but not
identical binding sites. This difference was found to reside in
few amino acid changes in the β-tubulin binding region (Gupta
et al., 2003). As described above, tau is an intrinsically disordered
and extended polypeptide that contains a microtubule binding
domain with three or four binding regions that allow binding
to several heterodimers at the microtubule lattice (Figure 1B).
These tubulin-binding regions are characterized by the presence
of prolines as well as basic residues to counteract the presence
of acidic residues at the C-terminus existing on the surface of
microtubules. It seems that binding to microtubules in different
heterodimers favors the stabilization of the microtubule and
such binding occurs in the same site where paclitaxel binds to
mammalian microtubules. Paclitaxel and discodermolide, among
others, compete with tau for binding the β-tubulin. In fact,
in polymerization experiments performed in the presence of
such kind of compounds, pelleted microtubules contain less tau
polypeptides. In addition, the sequence THVPGGN contained
in the tau binding domain is similar to the α-tubulin sequence
TVVPGGDL, present in its extended loop (Rowinsky and
Donehower, 1995). When for different reasons tau is detached
from microtubules, they become destabilized and also due to the
fact that tau is a disorganized protein with interacting surfaces
exposed, it tends to aggregate forming PHFs. This situation led to
the formation of neurofibrillary tangles (see below) and finally to
neuron death. In this case, induction of tau degradation might
be an important therapeutic approach. Chu et al. (2016) have
recently developed peptides derived from α- and β-tubulins that
recognized tau proteins connected to peptides recognized by E3
ubiquitin ligases and also to a cell penetrating peptide. They
found that some of these peptides induce tau poly-ubiquitination
and as a consequence its degradation in an AD mouse model
decreasing cytotoxicity (Chu et al., 2016).
Other Tau Binding Proteins
Actin or protein phosphatase 2A binds to tau, through tau repeats
(Correas et al., 1990; Bakota and Brandt, 2016). On the other
hand, taumotifs like PXXPmay interact withmembrane proteins
containing SH3 domains (Hwang et al., 1996) or with other
proteins, like Fyn tyrosine kinase that can be also localized at
the cell membrane (Lau et al., 2016). Tau, N-terminal region,
could be involved in the interaction with annexin A2 (Bakota and
Brandt, 2016).
The presence of exon 3 facilitates the binding of other
proteins such as ApoE, 14-3-3 zeta or synaptotagmin (Liu C.
et al., 2016). Also, tau interacts with alpha synuclein, probably
through the basic region containing residues 166–226 (Oikawa
et al., 2016). As mentioned above, tau interacts with other
microtubular proteins, such as the EB1 and EB3 proteins (7),
in developing neuronal cells. Characterization of tau binding
to EBs is currently under study. Also, tau can interact with
other proteins, like the RNA binding protein TIA1, through a
RNA intermediate (Vanderweyde et al., 2016). More recently,
the interaction of tau with other proteins like ferritin and
transferrin has been reported (Jahshan et al., 2016). Also, the
residues 139–143 could be involved in the binding to heparin
and the residues 336–343 and 347–351 could be involved in
chaperone mediated autophagy (Wang et al., 2009). By using
a protein-protein mining tool, the laboratory of Dr. Li Weil
in China (http://liweilab.genetics.ac.cn/tm/gene.php?st=gn&gn=
mapt&gi=4137&ti=9606) have described 172 genes related to tau
gene.
TAU SECONDARY STRUCTURE
Tau protein in solution can be considered as an intrinsically
disorder protein (IDP). It means that, as probed by different
techniques including circular dichroism (CD), Fourier transform
infrared spectroscopy (FTIR), X ray diffraction, fluorescence,
and some other methods, this protein behaves as a kind of
random coil, lacking a well-defined secondary structure (for
a full review on intrinsically disordered proteins, IDPs, see
reference Skrabana et al., 2006). Tau is a highly soluble and
heat-stable protein, in agreement with the lack of a well-defined
secondary and indeed tertiary structure. The first report on tau
protein structure (Cleveland et al., 1977) appeared 9 years before
PHFs were reported to be composed mainly of this protein
(Grundke-Iqbal et al., 1986a; Kosik et al., 1986; Nukina and
Ihara, 1986). The CD spectrum reported by Cleveland (Cleveland
et al., 1977) did not show any relevant secondary structure in a
significant extent. This lack of structure was confirmed later by
Woody et al. (1983) from proton NMR studies of microtubule-
associated proteins. A large number of proteins contain, along
their sequence, apparently unordered segments that, on the
other hand, possess a clearly defined function once they face
their interacting partners. This seems to be the particular case
of the so-called conformational diseases. Aggregation of totally
or partially disordered proteins has been repeatedly reported
to be associated with many human neurodegenerative diseases,
including Huntington’s, Creutzfeldt-Jakob’s, Parkinson’s, as well
as Alzheimer’s disease, and other neurodegenerative disorders as
the so-called tauopathies in the case of tau (Avila, 2006). However,
in most cases, and the tau protein is one of them, the molecular
mechanism of aggregation and even the fine structure of the
final aggregate—as it is the case for the PHFs formed by tau
protein—remains obscure and controversial.
Research on the secondary structure of tau protein is closely
tightened to that concerning the detailed molecular structure
of PHFs. Some months after the publication of the reports
confirming that tau protein was the main component of PHFs,
filaments resembling the PHF structure were obtained “in vitro”
from tau protein purified from porcine brain (Montejo de
Garcini et al., 1986). Thereafter, the door was open to study
the mechanism of tau aggregation leading to PHFs formation
and the subsequent search for the inhibition of the aggregation
process as a therapeutic target. However, obtaining PHFs from
tau protein resulted to be a not so easy task, and it seemed that
particular phosphorylation sites on tau had to be phosphorylated
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(Biernat et al., 1992; Wille et al., 1992). Most intriguing was to
reconcile the subtle helical structure found in PHFs with a tau
protein devoid of any relevant secondary structure, as deduced
fromCD and FTIR (Schweers et al., 1994). On the other hand, the
detailed molecular structure of PHFs has remained controversial
and at the same time no well-defined structure has been reported
for tau protein. Already in 1986, before tau was shown to be
the main component of PHFs, the characteristic reflection at
4.7 Angstrom, corresponding to a β-pleated sheet structure, was
reported to be found after X-ray diffraction on PHFs (Kirschner
et al., 1986). However, 8 years later, similarly to tau protein,
PHFs were reported to be devoid of any secondary structure,
as deduced from X-ray diffraction (Schweers et al., 1994). The
presence of β-amyloid in the PHFs preparation was considered as
a plausible explanation for the 4.7 Angstrom reflection reported
previously. Nevertheless, the same group reported later circular
dichroism and FTIR data of a tau derived peptide confirming a
pronounced β-structure on assembling. Their data indicated that
PHF assembly was dependent of a local sequence in tau protein,
at the beginning of the third repeat, forming β-structure (von
Bergen et al., 2000). Also, based on X-ray diffraction data, there
was a claim that peptides derived from tau protein—but not the
full-length protein—formed cross-β structure (Giannetti et al.,
2000). On the other hand, evidences for α-helix structure were
also reported. Based on CD and FTIR data, Sadqi et al. claimed
that PHFs isolated from brain samples of AD patients contained
a high proportion of α-helices (Sadqi et al., 2002). A percentage of
α-helix higher than β-sheet or unordered structure has also been
found for PHFs suspended in Tris buffer (Goux, 2002). A tau
fragment corresponding to themicrotubule-binding region of the
three repeat tau isoforms, as probed by high resolution NMR,
has revealed three regions involved in microtubules binding,
exhibiting a high preference for α-helix. A β-strand in a stretch
between two α-helix segments, alternatively, is involved in the
aggregation process to form PHFs (Eliezer et al., 2005). The
authors conclude that the cross-β structure might be limited
to short stretches at the core of the PHF structure, while α-
helices would be found within the core of the microtubule-
binding domain, as well as at the N- and C-terminal regions of
tau, therefore explaining the high content of α-helices reported
(Goux, 2002; Sadqi et al., 2002; Eliezer et al., 2005). This would
be in agreement with the observations of Kunjithapatham et al.
that proneness of tau to aggregate into α-helical structures
could be a consequence of its microtubule-binding capacity
(Kunjithapatham et al., 2005).
One of the main drawbacks to study tau protein structure
comes from its flexible and intrinsically disordered nature. This
type of proteins, offering a large population of conformations,
is not amenable to be studied by crystallographic methods.
Therefore, spectroscopy, particularly NMR, as well as CD and
Fourier Transform Infrared have been the most relevant sources
of structural information. The paper by Mukrasch et al. (2009)
is probably the most complete description of the full secondary
structure of the longest, 441 amino acid residues, and form of
tau protein. The NMR data reveal that 343 out of 441 amino
acids comprising tau are devoid of any ordered structure. Only
small segments of the sequence present transient elements of
secondary structure: six segments display propensity to form
β-strands, three segments show poly-Pro helices and, finally
two segments composed of ten amino acids, 114–123 and
428–437, within the N-terminal projection domain and the C-
terminal domain present transient α-helix structure (Mukrasch
et al., 2009; Wang and Mandelkow, 2016). No relevant sequence
homology has been found for the 428–437 segment displaying α-
helix propensity. On the other hand the α-helix segment at the
projection domain 114–123 presents homology with an α-helix
segment on cytochrome B5 (Qian et al., 2001). Most interesting
is the finding that tau protein, in agreement with previous
reports, presents a highly dynamic structure with many compact
conformations and a complex network of long range transient
contacts. This description is far from the elongated molecule
originally described from electronmicroscopy (Wille et al., 1992),
and is closer to the hairpin structure in which both N- and
C-terminals contacted with each other (Jeganathan et al., 2006).
Tau protein has a large number of potential sites of
phosphorylation (Grundke-Iqbal et al., 1986b; Bancher et al.,
1989; Wang and Mandelkow, 2016), 80 Ser or Thr and 5 Tyr.
The phosphorylation state of the protein is developmentally
regulated and closely related to its function. Phosphorylation is
involved in regulating the interaction with different partners as
microtubules and nucleic acids (Camero et al., 2014; Multhaup
et al., 2015), in the protein location and, indeed it is related
to the PHF and tangles formation (Wang and Mandelkow,
2016). In fact one of the initial observations related to the
abnormal tau aggregation into PHFs was that tau within
this complexes is abnormally hyper-phosphorylated (Grundke-
Iqbal et al., 1986b). Tau protein is a dynamic structure
displaying a complex network of intramolecular long-range
interactions, lacking a well-defined secondary structure -except
for a number of short segments displaying some transient
proneness to acquire particular structural elements. On the other
hand, phosphorylation regulates all tau functions: development,
spreading and location, partners interaction and of course PHFs
formation and evolution, leading therefore to the question: how
does phosphorylation affect the secondary structure of tau? After
some mutations or serine and threonine residues in tau into
glutamic acid, Bibow et al. have suggested that phosphorylation
might induce the opening of the transient folded structure of
tau (Bibow et al., 2011). Finally, NMR experiments carried
out on a peptide derived from tau protein have shown how
phosphorylation stabilizes the α-helix structure on tau (Sibille
et al., 2012), therefore suggesting the possibility of a higher
content of α-helices in the hyper-phosphorylated tau building
PHFs.
TAU TERTIARY STRUCTURE
Electron microscopy analysis done by Hirokawa’s group
(Hirokawa et al., 1988) suggested that tau could have an extended
fibrillar form. However, by looking at the epitopes recognized by
the antibody Alz50, it was found that such antibody reacts with
residues present at the N- and C-terminal regions, suggesting a
possible tertiary structure in tau protein (Carmel et al., 1996).
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Although, nuclear magnetic resonance and small-angle X-ray
scattering indicate that tau is an intrinsically disordered protein
(Qi et al., 2015), a “paper-clip” structure has been suggested for
some molecules of tau monomers. This model was obtained
by FRET measurements on tryptophan mutants of tau protein
(Jeganathan et al., 2006). The presence of a “paper-clip” structure
may suggest the presence of intramolecular interactions between,
at least, two different regions of tau molecule. If one of those
regions is involved in tau self-interaction, the opening of the
“paper-clip” structure could facilitate that self-aggregation (see
Figure 1C). As indicated, tau is an intrinsically disordered
protein and methods to determine its tertiary structure like
X-ray crystallography could not be suitable to describe that
structure and nuclear magnetic resonance (NMR) studies could
be advisable to do it (Lippens et al., 2016).
NMR spectroscopy of isolated tau have shown some
conformational changes upon phosphorylation of tau at its
threonine 231, suggesting the stabilization of a small α-helix at
that region (Sibille et al., 2012); or upon phosphorylation at the
Ser 202 and Thr 205, a modification that could be recognized by
AT8 antibody. Thus, modification of those sites could result in an
unusual turn conformation (Gandhi et al., 2015).
TAU QUATERNARY STRUCTURE
Tau protein could form dimers, oligomers and larger polymers.
In the formation of tau dimers or oligomers, cysteine residues
may play an important role (Takashima, 2013; Soeda et al.,
2015). These cysteine residues are present at the microtubule-
binding domain (MTBD) of tau protein that is also involved
in tau-tau interaction. Nevertheless, for the formation of
tau aggregates or fibers, it is not essential the formation of
intramolecular cysteine_cysteine links, and the formation of tau
fibers could be facilitated by the presence of polyanions like
heparin (Huvent et al., 2014). It is discussed if tau dimers
could be toxic (Cowan and Mudher, 2013), but there is some
evidence indicating that tau trimers could be the toxic species
(Tian et al., 2013). Larger granular tau oligomers, composed
by around 36 tau molecules have been also described as
possible toxic agents (Maeda et al., 2007). These oligomers
may precede the formation of tau filaments found in different
tauopathies. In Alzheimer disease, mainly two types of tau
filaments have been described: paired helical (PHF) or straight
(SF) filaments. By doing “in vitro” analysis, it has been
proposed that a difference between PHFs and SFs could
be the presence, in PHFs, of sulfated glycosaminoglycans,
like heparan sulfate or chondroitin sulfate, associated to tau
polymers (Arrasate et al., 1997). On the other hand, highly
sulfated, heparan sulfate (heparin) facilitates tau aggregation to
form filaments (Goedert et al., 1996; Pérez et al., 1996). In
addition, glycation of tau filaments results in the formation
of larger aggregates similar to neurofibrillary tangle aggregates
(Ledesma et al., 1996).
Tau aggregates and fibrils could have a role in tau spreading.
Tau spreading has been a hot topic within recent years
(Clavaguera et al., 2009; Sanders et al., 2014; Peeraer et al., 2015).
However, since this review is focused on the structure and not
in the (toxic) function of tau aggregates, we enclosed reference
(Wang and Mandelkow, 2016) for a good review of that topic.
It has been described that tau filaments are assembled by
the self-association of tau molecules (Montejo de Garcini et al.,
1986), in an anti-parallel arrangement, through theMTBDs. That
arrangement could facilitate the interaction through cysteine
and other residues present in that domain (Ksiezak-Reding and
Yen, 1991; see Figure 2). Tau fragments containing the MTBD
could also assemble into fibrillar polymers (Hirokawa et al., 1988;
Jeganathan et al., 2006) and even a very small fragment composed
by the hexapeptide VQIVYK, present in the MTBD, is able to
form filaments (von Bergen et al., 2000).
On the other hand, when tau molecules are bound to
microtubules, the MTBD is not accessible to facilitate tau-tau
association. However, it has been reported that tau, bound to
microtubules, could form dimers through its N-terminal region
(Feinstein et al., 2016). These regions and also, perhaps, the C-
terminal region could play a role in the spatial organization of
axonal microtubules, keeping parallel microtubules despite of
macromolecular crowding (Méphon-Gaspard et al., 2016).
Although mainly fibrillar polymers could be obtained “in
vitro,” using only pure tau proteins, the assembly of the protein
could be facilitated upon addition of anionic compounds (see for
example Avila et al., 2004, for a review). These fibrillary structures
are dynamic polymers, as shown in cell culturemodels (Guo et al.,
2016).
Apart from fibrillary structures there are other tau polymers
showing different structures like Pick’s bodies or argylophilic
grains, among others (see for example Rábano et al., 2013).
The assembly of those structures could be facilitated by the
presence of other compounds or by differences in the level of
tau phosphorylation. Indeed phospho-tau dephosphorylation by
protein phosphatase 2A could switch the formation of fibrillary
polymers to argylophilic gain-like morphology (Hu et al., 2016).
Curiously, injection in mouse brain of brain extracts from
patients with tauopathies showing different tau structures could
reproduce “in vivo” the appearance, in mouse, of those structures
(Clavaguera et al., 2013; Sanders et al., 2014). It suggests that
some additional compounds, in addition to tau, could be involved
in raising the final morphology of tau structures. Also, those
FIGURE 2 | Interaction tau-tau. Tau protein could be found as an extended
common long protein that could bind to other proteins, including itself, in this
extended fashion (Hirokawa et al., 1988). The Figure shows how two tau
molecules could interact, in an antiparallel fashion, through their
microtubule-binding domain where cysteine residues are present.
Frontiers in Aging Neuroscience | www.frontiersin.org 6 November 2016 | Volume 8 | Article 262
Avila et al. Tau Structures
FIGURE 3 | Hypothetical tau circular-like structure. (A) Tau granule
(circular-like) structures have been previously reported (Rábano et al., 2013;
Takashima, 2013). In the Figure, it is shown an hypothetical closed structure
playing with parallel and antiparallel tau molecules. In that structure, a hole in
the center surrounded by C-terminal sequences of tau molecule can be found.
Since tau C-terminal sequences contain several acidic residues, it is possible
the reaction of those residues with metals. It may take place in argylophylic
grains. (B) A 3D-like image of the structure is shown. In that image parallel and
antiparallel forms, with the C-terminal (blue) or N-terminal (violet), regions of tau
molecule at the surface, could be present. It is proposed that those having the
C-terminal inside the structure could react with cations.
different morphologies could be the consequence of different
arrangements of tau molecules, which could be found either
in parallel form, mixed of parallel and anti-parallel forms, or
anti-parallel form (see Figure 3). For example the hypothetical
structure shown in Figure 3 could be the result of assembly of
parallel and antiparallel forms. Some of them could aggregate
around a cationic (metal) structure, whereas other could form
antiparallel aggregates. Also, recently, has been shown that
different structures could arise from the mixture of full length
tau and tau fragments (Ozcelik et al., 2016). Nevertheless, when
the injection in mouse brain was done using only synthetic tau
protein, mainly fibrillar polymers were obtained (Iba et al., 2013).
Although, in a general way, it has been suggested the transition
from soluble monomeric tau protein to the formation of large,
insoluble, tau aggregates (Takashima, 2013), more studies are
needed to test if tau protein follows a protein phase transition in
a similar way to that described for the formation of FUS protein
aggregates in amyotrophic lateral sclerosis (Patel et al., 2015).
Recent findings have established that a variety of intracellular
membrane-less organelles and micro-compartments behave as
liquid droplets inside the cell that are formed by liquid phase
transitions from cytoplasm, suggesting that phase separation
play an important role in the functional organization of the
cell (Hyman and Simons, 2012). Intrinsic disordered proteins
containing low complexity domains (LCD) prone to aggregate
have been shown to be more susceptible to phase separate
(Hyman and Simons, 2012; Aguzzi and Altmeyer, 2016). In
this regard, the assembly of FUS into dynamic non-membrane
compartments was found to be dependent on the prion-like
domain of the protein, a type of LCD, which is thought to be
involved in the formation of toxic aggregates (Patel et al., 2015).
In fact, this domain is also present in tau protein and other
aggregation-prone proteins associated to aging diseases. Time-
dependent FUS aggregation led to the formation of disease-
linked solid aggregates and aberrant liquid to solid phase
transition was accelerated by ALS patient mutations, suggesting
that the pathological aggregates could result from unregulated
phase transitions linked to protein modifications that alter its
assembly properties. Therefore, factors modulating the relative
abundance of the different aggregation states of an amyloid
forming protein [as glycosylation (Liu K. et al., 2016) or
crowding (Wu et al., 2015) in the case of tau protein] may
have a major impact in the formation of dynamic liquid micro-
compartments and in the liquid-to-solid phase transition leading
to pathological aggregation. The maintenance of the proper
balance of physiological phase transitions may constitute a novel
therapeutic strategy against neurodegeneration.
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